Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Hellmis

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Seizure|December 29, 2007
Sexual problems in males with epilepsy--an interdisciplinary challenge!Eva Hellmis
Der Urologe. Ausg. A|February 12, 2021
[Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis]Boris Hadaschik, Eva Hellmis
Aktuelle Urologie|March 27, 2023
[Prostate Cancer: Side-Effect Management for Androgen Deprivation Therapy]Eva Hellmis, Tobias Niels Mudra, Axel S Merseburger
Aktuelle Urologie|March 19, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
Aktuelle Urologie|February 23, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
The Journal of Nutrition|December 25, 2007
Lycopene inhibits disease progression in patients with benign prostate hyperplasiaSilke Schwarz, Ute C Obermüller-Jevic, Eva Hellmis, et al.
Aktuelle Urologie|September 27, 2022
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]Charlotte Jores, Frank König, Eva Hellmis, et al.
Future Oncology (London, England)|April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
Aktuelle Urologie|October 24, 2022
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]Charlotte Jores, Frank König, Eva Hellmis, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Seizure|December 29, 2007
Sexual problems in males with epilepsy--an interdisciplinary challenge!Eva Hellmis
Der Urologe. Ausg. A|February 12, 2021
[Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis]Boris Hadaschik, Eva Hellmis
Aktuelle Urologie|March 27, 2023
[Prostate Cancer: Side-Effect Management for Androgen Deprivation Therapy]Eva Hellmis, Tobias Niels Mudra, Axel S Merseburger
Aktuelle Urologie|March 19, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
Aktuelle Urologie|February 23, 2021
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program]Eva Hellmis, Christian Schwentner, Philipp Mandel, et al.
The Journal of Nutrition|December 25, 2007
Lycopene inhibits disease progression in patients with benign prostate hyperplasiaSilke Schwarz, Ute C Obermüller-Jevic, Eva Hellmis, et al.
Aktuelle Urologie|September 27, 2022
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]Charlotte Jores, Frank König, Eva Hellmis, et al.
Future Oncology (London, England)|April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
Aktuelle Urologie|October 24, 2022
[Retrospective practice-related care research study on therapy of mCPRC with radium-223 dichloride]Charlotte Jores, Frank König, Eva Hellmis, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
Pageof 2